The Benefit and clinical characteristics after use of Nintedanib in Idiopathic Pulmonary Fibrosis
Benefit and clinical characteristics after use of Nintedanib in Idiopathic Pulmonary Fibrosis
Keywords:Key words: idiopathic fibrosis, nintedanib, monotherapy.
Nintedanib is an approved antifibrotic agent for the treatment of idiopathic pulmonary fibrosis. (FPI) as monotherapy. To date, the evidence supports its effectiveness in this type of patients. We present a case of a Mexican patient of 69 years with Idiopathic Pulmonary Fibrosis (IPF) treated with nintedanib for 6 months as monotherapy in a university hospital. Before the 52 week period. There was a clear decrease in the patient's forced vital capacity (FVC) from 70% (2.14L) to 60% (1.83L). The treatment with nintedanib was started for a period of 12 months at a dose of 150 mg VO every 12 hrs. Lung function stabilized increasing from 60% (1.83L) to 70% (2.14L), the treatment was well tolerated. Only with presence of mild adverse effects without repercussions.
We describe the successful case of a patient with Idiopathic Pulmonary Fibrosis after 52 weeks of treatment with Nintedanib, well tolerated and with improved lung function, until now the antifibrotic therapy represents a safe and therapeutically option as monotherapy.